

Artificial Vision




Introduzione

- La visione è una complessa forma di trasmissione dati che processa informazioni che dipendono da un importante neuro-processore: la retina umana.
- Le informazioni visive ottenute dalla retina (circa **130 milioni di fotorecettori**) sono compresse e trasformate in segnali elettrici veicolati da circa 1.2 milioni di cell ganglionari, neuroni specializzati i cui assoni formano il nervo ottico.


Chi ha bisogno di una retina artificiale?



Retinal diseases affect different layers




Retinal diseases affect different layers




Retinite Pigmentosa

- Nella RP, la degenerazione periferica dei fotorecettori causa la riduzione del campo visivo, mentre l'acuità visiva è inizialmente conservata
- Si sviluppa così l'aspetto classico del fondo con pigmento a spiccole ossee



Successivamente anche i fotorecettori centrali degenerano, causando la perdita totale della visione


Developed Countries



30,000,000

People with Outer Retinal Diseases


Che cos'è la retina artificiale?



Sistema che elabora il segnale luminoso trasformandolo in segnale elettrico che viene trasmesso alle cellule gangliari della retina e, di conseguenza, alle vie ottiche.


Vengono bypassati i fotorecettori

Che cos'è la retina artificiale?



Attualmente 2 diversi impianti:

- Epiretinico
- Sottoretinico






Doheny – USC & Second Sight




Los Angeles, CA




Mark Humayun, MD PhD

Meccanismo di Azione










Argus 2



Dept of Energy 2009

Two Devices, Two Trials

Argus I – feasibility study


- 16 electrodes
- 6 Subjects-single surgeon
- Practical Implant Proof of Concept – chronic stimulation over 6 years in patients.



Argus I

Argus II – prospective trial

- 60 electrodes
- 32 subjects implanted to date
- Aimed at demonstrating safety and efficacy.



Argus II



Performance with System

- All subjects see phosphenes
- All subjects use the system at home

- Object Localization
- Motion Discrimination
- Orientation and Mobility
- Visual Acuity Testing



Conclusions

Argus II trial is the largest study of a retinal prosthesis to date and the only FDA-approved IDE study.

The results demonstrate that the Argus II system (like the Argus I) can reliably withstand long-term implant with a reasonable safety profile.


Using the system, all blind subjects are able to detect light and improve their performance on some visual tasks.

We look forward to presenting longer follow-up on even more Argus II subjects with the recent government expansion approvals in Europe and the US.



*University of
Tübingen*


*Tübingen,
Germany*






Subretinal Implant Project

*Prof. Dr. med. Eberhart Zrenner
University of Tübingen*





Come Funziona?

- Impianto ATTIVO con **elementi sensibili alla luce** capaci di sostituire in parte la funzione dei fotorecettori danneggiati lavorando a livello del corrispondente strato retinico.
- Ogni fotocellula sulla superficie del chip trasforma l'energia luminosa in energia elettrica in modo da stimolare la retina sulla base della intensità di stimolazione luminosa locale





Dove si inserisce il CHIV ALPHA?




Spessore: 100 microns (1/10 mm), come un capello umano

The complete subretinal implant




- **Chip:** 1500 Microphotodiodes, Amplifiers and TiN electrodes,

Schema completo dell'impianto



1. CMOS chip (on PI-foil) with protective trocar sleeve (shown above)
2. PI-foil (length 30 – 50 mm, or patient specific size)
3. Silicone patch for fixation to sclera (form & size may change patient specifically)
4. Ceramic tile (connects PI-foil to power cable; sits on top of silicone patch)
5. Power cable (may have return electrode-shell & patient specific length 150 – 250 mm)
6. Ceramic housing with power cable and separate return electrode


Come si alimenta ?



L'energia necessaria raggiunge il chip attraverso un **cavo di silicone** che è inserito sotto il **muscolo massetere** e connesso a una **scatoletta di ceramica** dietro l'orecchio sotto la cute

All'esterno non si vede niente

Tubingen sub-retinal implant



Prospective pilot study

2005 -2008



(after 10 years of preclinical work)

testing subretinal electrode arrays safety and efficacy

- Patients with hereditary retinal degeneration
- Blind, no useful vision (possibly light perception without localization)
- Implant testing period: 4 weeks, Pat. 1-8
3 months, Pat. 9-12

The Pilot Study results

- 11 patients have been implanted
- no significant negative effect on surrounding tissue could be detected



OP

Patient 7

8


9

10

11

12


Pre-OP




Post-OP

IMPLANTATION


1-9d



9 - 20d




20 - 40d




EXPLANTATION

>40d




vitrectomy




subretinal bleb


preparation of the choroid




**Transchoroidal
implantation**



Extraocular fixation






creating healon-bubble

Tests performed with the light stimulation of the „chip“ 7 pictures per second, 0,5 ms duration, 1500 pixels

Continous perception of:

- Stripe patterns
- Landolt rings
- Objects
- Letters



Four alternative forced choice test
With chip „ON“ and chip „OFF“


Video lettura

Conclusions


- ❑ It is apparently necessary to place the chip right under the macula, utilizing all the power of the papillomacular bundle that is highly represented in the brain
- ❑ It can be estimated that at least 1000 electrodes in a 10 degree field are necessary to achieve such spatial resolution
- ❑ Subretinal active implant is the only device worldwide so far that is able to provide this high spatial resolution to patients



Optobionics, Inc



Chicago, IL



Subretinal Artificial Silicon Retina Microchip for Treatment of Retinitis Pigmentosa:

10 Patient Pilot Study = 2 1/2 to 5 Yr Update

^{1,2,*}A.Y.Chow, ^{2,*}K.H. Packo, ^{2,*}J.S. Pollack, ³R. Schuchard


¹*Optobionics Corporation*

²*Rush University Medical Center*


³*Atlanta VA Medical Center*

Emory University

* Financial Interest





Retinal Prosthesis Implantation





Prosthesis partially introduced through retinotomy

ASR chip well tolerated after 4.5 - 5 years (Patients 1-3)



1



2




3




Optical Coherence Tomography

Normal retinal thickness over ASR




High reflectivity artifact

Reading ETDRS Chart



Zero Letters Read Preoperatively

Progress of the Artificial Retina





**Grazie per
l'attenzione**